Teva and Alvotech Announce Strategic Partnership to Collaborate in the U.S. Biosimilar Market
August 05, 2020
View all news
- Teva and Alvotech bring together highly complementary capabilities to secure a leading position in the U.S. biosimilar market
- The collaboration is one of the broadest partnerships within the U.S. biosimilar industry to date to accelerate improved patient access for high quality biosimilar medicines in the U.S. biosimilar industry
View source version on?businesswire.com:?https://www.businesswire.com/news/home/20200805005390/en/
Media: Alvotech Halldor Kristmannsson Halldor.kristmannsson@alvotech.com Tel: +354 522-2900 Source: Teva Pharmaceutical Industries Ltd.